Varicella Zoster Virus (VZV) is a double-stranded DNA virus belonging to the Herpesviridae family. It is responsible for causing two distinct clinical conditions: chickenpox (varicella) and shingles (herpes zoster). Chickenpox, primarily affecting children, manifests as a highly contagious illness characterized by a widespread, itchy rash. VZV establishes latency in sensory ganglia following the primary infection. Later in life or during periods of immunosuppression, the virus may reactivate, leading to shingles—a painful, localized rash with a dermatomal distribution. The primary mode of VZV transmission is through respiratory droplets or direct contact with skin lesions. While chickenpox is usually a self-limiting disease, shingles can result in long-term complications such as postherpetic neuralgia. Vaccination, with the Varicella vaccine for chickenpox and the Zoster vaccine for shingles, has proven effective in preventing or reducing the severity of both conditions. Antiviral medications can also be prescribed to manage active infections and alleviate symptoms. Understanding the pathogenesis of VZV, its transmission dynamics, and the complications associated with chickenpox and shingles is crucial for public health initiatives, vaccination strategies, and clinical management. Ongoing research aims to enhance our knowledge of VZV, improving preventive measures and treatment options for individuals affected by these related viral diseases.